Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell ...

How Does Blenrep Work for Multiple Myeloma? Blenrep is an antibody-drug conjugate (ADC), which is a type of targeted cancer medicine. ADCs contain two parts, a protein called an antibody and an ...

Regeneron Pharmaceuticals is expanding its cancer drug lineup with FDA approval of a bispecific antibody it developed for multiple myeloma, the second most common type of blood cancer. In multiple ...

How Does Multiple Myeloma Impact the Kidneys? Multiple myeloma is a cancer of plasma cells, a type of immune cell found in bone marrow. Healthy plasma cells make proteins called antibodies to fight ...

Luciano Costa waited three years to see how patients with an aggressive bone-marrow cancer would fare on an experimental immunotherapy treatment. Reviewing the results gave him goose bumps. “Holy shit ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

Researchers have created the first detailed molecular map of the human bone marrow, revealing new insights that could reshape our thinking about how an incurable blood cancer grows and spreads.